Identification/NN
of/IN
Gene/NN
Expression/NN
Signatures/NNS
in/IN
Korean/JJ
./.
====================
Acute/JJ
Leukemia/NN
Patients/NNS
====================
Back/NN
g/NN
ro/NN
und/JJ
:/:
In/IN
acute/JJ
leukemia/NN
patients/NNS
,/,
several/JJ
successful/JJ
====================
methods/NNS
of/IN
expression/NN
profiling/VBG
have/VBP
been/VBN
used/VBN
for/IN
various/JJ
purposes/NNS
,/,
i.e./FW
,/,
to/TO
identify/VB
new/JJ
disease/NN
class/NN
,/,
to/TO
select/VB
a/DT
therapeutic/JJ
target/NN
,/,
or/CC
to/TO
predict/VB
chemo-sensitivity/NN
and/CC
clinical/JJ
outcome/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
tested/VBD
the/DT
peripheral/JJ
blood/NN
of/IN
47/CD
acute/JJ
leukemia/NN
patients/NNS
in/IN
an/DT
attempt/NN
====================
to/TO
identify/VB
differentially/RB
expressed/VBN
genes/NNS
in/IN
AML/NN
and/CC
ALL/NN
using/VBG
a/DT
Korean-made/NN
10K/NN
oligo-nucleotide/NN
microarray/NN
./.
====================
Methods/NNS
:/:
Total/JJ
RNA/NN
was/VBD
prepared/VBN
from/IN
peripheral/JJ
blood/NN
and/CC
amplified/VBN
for/IN
microarray/NN
experimentation/NN
./.
====================
SAM/NN
(/(
significant/JJ
analysis/NN
of/IN
microarray/NN
)/)
and/CC
PAM/NN
(/(
prediction/NN
analysis/NN
of/IN
microarray/NN
)/)
were/VBD
used/VBN
to/TO
select/VB
significant/JJ
genes/NNS
./.
====================
The/DT
selected/VBN
genes/NNS
were/VBD
tested/VBN
for/IN
in/IN
a/DT
test/NN
group/NN
,/,
independently/RB
of/IN
the/DT
training/VBG
group/NN
./.
====================
Results/NNS
:/:
\Ne/JJ
identified/VBN
345/CD
differentially/RB
expressed/VBN
genes/NNS
that/WDT
differentiated/VBD
AML/NN
and/CC
ALL/NN
patients/NNS
(/(
FWER/NN
</JJR
0.05/CD
)/)
./.
====================
Genes/NNS
were/VBD
selected/VBN
using/VBG
the/DT
training/VBG
group/NN
(/(
n=35/CD
)/)
and/CC
tested/VBN
for/IN
in/IN
the/DT
test/NN
group/NN
(/(
n=12/NN
)/)
./.
====================
Both/DT
training/VBG
group/NN
and/CC
test/NN
group/NN
discriminated/VBD
AML/NN
and/CC
ALL/NN
patients/NNS
accurately/RB
./.
====================
Genes/NNS
that/WDT
showed/VBD
relatively/RB
high/JJ
expression/NN
in/IN
AML/NN
patients/NNS
were/VBD
deoxynucleotidyl/JJ
transferase/NN
,/,
pre-B/JJ
lymphocyte/NN
gene/NN
3/CD
,/,
B-cell/NN
linker/NN
,/,
CD9/NN
antigen/NN
,/,
lymphoid/JJ
enhancer-binding/JJ
factor/NN
1/CD
,/,
CD79B/NN
antigen/NN
,/,
and/CC
early/JJ
B-cell/NN
factor/NN
./.
====================
Genes/NNS
highly/RB
expressed/VBN
in/IN
ALL/NN
patients/NNS
were/VBD
annexin/NN
A1/NN
,/,
amyloid/NN
beta/NN
(/(
A4/NN
)/)
precursor/NN
protein/NN
,/,
amyloid/NN
beta/NN
(/(
A4/NN
)/)
precursor-like/JJ
protein/NN
2/CD
,/,
cathepsin/NN
C/NN
,/,
lysozyme/NN
(/(
renal/JJ
amyloidosis/NN
)/)
,/,
myeloperoxidase/JJ
,/,
and/CC
hematopoietic/JJ
prostaglandin/NN
D2/NN
synthase/NN
./.
====================
Conclusion/NN
:/:
This/DT
study/NN
provided/VBD
genome/NN
wide/JJ
molecular/JJ
signatures/NNS
of/IN
Korean/JJ
acute/JJ
leukemia/NN
patients/NNS
,/,
which/WDT
clearly/RB
identify/VBP
AML/NN
and/CC
ALL/NN
./.
====================
Given/IN
with/IN
other/JJ
reported/VBN
signatures/NNS
,/,
these/DT
molecular/JJ
signatures/NNS
provide/VBP
a/DT
means/NN
of/IN
achieving/VBG
a/DT
molecular/JJ
diagnosis/NN
in/IN
Korean/JJ
acute/JJ
leukemia/NN
patents/NNS
./.
====================
The/DT
exact/JJ
diagnosis/NN
and/CC
classification/NN
of/IN
acute/JJ
leukemias/NNS
are/VBP
of/IN
clinical/JJ
importance/NN
due/JJ
to/TO
the/DT
different/JJ
treatment/NN
approaches/NNS
required/VBD
./.
====================
Acute/JJ
myelogenous/JJ
leukemia/NN
(/(
AML/NN
)/)
is/VBZ
a/DT
malignant/JJ
disease/NN
of/IN
the/DT
bone/NN
marrow/NN
in/IN
which/WDT
hematopoietic/JJ
precursors/NNS
are/VBP
transformed/VBN
and/CC
arrested/VBN
in/IN
an/DT
earlier/RBR
stage/NN
of/IN
development/NN
./.
====================
AML/NN
is/VBZ
diagnosed/VBN
on/IN
the/DT
presence/NN
of/IN
greater/JJR
than/IN
20/CD
%/NN
blasts/NNS
in/IN
the/DT
marrow/NN
(/(
Jaffe/NN
eta/./FW
,/,
2001/CD
)/)
./.
====================
Acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
ALL/NN
)/)
is/VBZ
also/RB
a/DT
malignant/JJ
clonal/JJ
disease/NN
of/IN
the/DT
bone/NN
marrow/NN
in/IN
which/WDT
early/JJ
lymphoid/JJ
precursors/NNS
proliferate/VBP
and/CC
replace/NN
the/DT
normal/JJ
hematopoietic/JJ
cells/NNS
of/IN
the/DT
marrow/NN
./.
====================
Although/IN
AML/NN
and/CC
ALL/NN
are/VBP
distinct/JJ
clinical/JJ
and/CC
morphological/JJ
disease/NN
entities/VBZ
,/,
no/DT
single/JJ
test/NN
is/VBZ
currently/RB
capable/JJ
of/IN
differentiating/VBG
them/PRP
./.
====================
The/DT
classification/NN
proposed/VBN
by/IN
the/DT
French-American-British/JJ
(/(
FAB/NN
)/)
is/VBZ
based/VBN
on/IN
morphology/NN
and/CC
cytochemistry/NN
,/,
and/CC
involves/VBZ
eight/CD
major/JJ
subtypes/NNS
,/,
i.e./FW
,/,
M0/NN
to/TO
M7/NN
(/(
Bennet/NNP
etal./FW
,/,
1976/CD
;/:
Bennet/NNP
etal./FW
,/,
1985/CD
)/)
./.
====================
The/DT
new/JJ
World/NN
Health/NN
Organization/NN
(/(
WHO/NN
)/)
classification/NN
incorporates/VBZ
molecular/JJ
,/,
cytogenetic/JJ
,/,
and/CC
clinical/JJ
features/NNS
with/IN
morphology/NN
(/(
Jaffe/NN
et/FW
al./FW
,/,
2001/CD
)/)
,/,
and/CC
provides/VBZ
new/JJ
prognostic/JJ
markers/NNS
and/CC
suggests/VBZ
disease-specific/JJ
therapeutic/JJ
approaches/NNS
./.
====================
For/IN
example/NN
,/,
all-trans-retinoic/JJ
acid/NN
and/CC
arsenic/JJ
trioxide/NN
have/VBP
revolutionized/VBN
the/DT
treatment/NN
of/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
characterized/VBN
by/IN
t/NN
(/(
15:17/CD
)/)
(/(
q22/NN
:/:
q21/CD
)/)
(/(
Kelly/RB
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
However/RB
,/,
the/DT
standard/JJ
diagnostic/JJ
methods/NNS
required/VBN
for/IN
leukemia/NN
are/VBP
complex/NN
,/,
time-consuming/JJ
,/,
and/CC
require/VB
experienced/VBN
specialists/NNS
./.
====================
Moreover/RB
,/,
the/DT
diagnoses/NNS
of/IN
some/DT
patients/NNS
remain/VBP
obscure/JJ
based/VBN
on/IN
current/JJ
classifications/NNS
./.
====================
In/IN
addition/NN
,/,
therapeutic/JJ
strategies/NNS
determined/VBN
on/IN
the/DT
basis/NN
of/IN
classification/NN
are/VBP
unsatisfactory/JJ
./.
====================
For/IN
example/NN
,/,
the/DT
most/JJS
appropriate/JJ
treatment/NN
for/IN
standard-risk/NN
AML/NN
,/,
which/WDT
accounts/VBZ
for/IN
over/IN
half/NN
of/IN
all/DT
cases/NNS
of/IN
this/DT
disease/NN
,/,
has/VBZ
not/RB
been/VBN
firmly/RB
established/VBN
./.
====================
Moreover/RB
,/,
this/DT
subgroup/NN
is/VBZ
difficult/JJ
to/TO
classify/VB
,/,
because/IN
it/PRP
includes/VBZ
cases/NNS
with/IN
various/JJ
numerical/JJ
and/CC
structural/JJ
cytogenetic/JJ
abnormalities/NNS
that/IN
occur/VBP
infrequently/RB
,/,
which/WDT
makes/VBZ
it/PRP
difficult/JJ
to/TO
determine/VB
their/PRP$
prognostic/JJ
significances/NNS
(/(
Grimwade/NNP
etal./FW
,/,
2001/CD
)/)
./.
====================
Moreover/RB
,/,
cytogenetic/JJ
analysis/NN
provides/VBZ
no/DT
clues/NNS
in/IN
cases/NNS
of/IN
AML/NN
with/IN
a/DT
normal/JJ
karyotype/NN
,/,
which/WDT
account/VBP
for/IN
the/DT
majority/NN
of/IN
cases/NNS
in/IN
the/DT
standard-risk/NN
group/NN
./.
====================
Gene/NN
expression/NN
profiles/NNS
have/VBP
recently/RB
been/VBN
featured/VBN
in/IN
research/NN
programs/NNS
concerning/VBG
hematologic/JJ
malignancies/NNS
./.
====================
The/DT
diagnosis/NN
and/CC
classification/NN
of/IN
leukemia/NN
have/VBP
been/VBN
mainly/RB
issued/VBN
for/IN
several/JJ
years/NNS
./.
====================
Golub/NN
et/FW
al/JJ
./.
====================
successfully/RB
classified/VBN
AML/NN
and/CC
ALL/NN
using/VBG
molecular/JJ
signatures/NNS
(/(
Golub/NN
et/FW
al./FW
,/,
1999/CD
)/)
,/,
and/CC
the/DT
studies/NNS
by/IN
Bullinger/NN
et/FW
al/JJ
./.
====================
(/(
Bullinger/NNP
et/FW
al./FW
,/,
2004/CD
)/)
and/CC
Valk/NN
et/FW
al/JJ
./.
====================
(/(
Valk/NN
et/FW
al./FW
,/,
2004/CD
)/)
suggested/VBD
that/IN
molecular/JJ
classifications/NNS
based/VBN
on/IN
gene/NN
expression/NN
profiles/NNS
could/MD
provide/VB
more/RBR
accurate/JJ
diagnoses/NNS
and/CC
classifications/NNS
and/CC
predict/VBP
clinical/JJ
outcomes/NNS
better/RBR
./.
====================
Bullinger/RBR
et/FW
al/JJ
./.
====================
identified/VBN
a/DT
new/JJ
molecular/JJ
subtype/NN
of/IN
AML/NN
that/DT
includes/VBZ
two/CD
prognostically/RB
relevant/JJ
subgroups/NNS
of/IN
AML/NN
with/IN
a/DT
normal/JJ
karyotype/NN
./.
====================
Valk/NN
et/FW
al/JJ
./.
====================
reported/VBN
several/JJ
novel/JJ
clusters/NNS
,/,
some/DT
consisting/VBG
of/IN
specimens/NNS
with/IN
a/DT
normal/JJ
karyotype/NN
and/CC
a/DT
unique/JJ
cluster/NN
in/IN
a/DT
patient/NN
with/IN
a/DT
poor/JJ
clinical/JJ
outcome/NN
./.
====================
Several/JJ
clusters/NNS
identified/VBD
by/IN
Schoch/JJ
etal/JJ
./.
====================
(/(
Schoch/NNP
eta/NN
!/CD
./.
,/,
2002/CD
)/)
and/CC
Debernardi/NN
etal/JJ
./.
====================
(/(
Debernardi/NNP
et/FW
al./FW
,/,
2003/CD
)/)
were/VBD
found/VBN
to/TO
correspond/VB
to/TO
cytogenetic/JJ
and/CC
molecular/JJ
definitions/NNS
,/,
such/JJ
as/IN
,/,
t/NN
(/(
15/CD
;/:
17/CD
)/)
,/,
t/NN
(/(
8/CD
;/:
21/CD
)/)
,/,
and/CC
inv/NN
(/(
16/CD
)/)
./.
====================
These/DT
,/,
collectively/RB
,/,
reflect/VBP
that/DT
genome-wide/VBP
expression/NN
profiles/NNS
and/CC
can/MD
be/VB
integrated/VBN
into/IN
clinical/JJ
practice/NN
to/TO
broaden/JJ
our/PRP$
understanding/NN
of/IN
these/DT
diseases/NNS
./.
====================
Here/RB
,/,
we/PRP
report/VBP
on/IN
an/DT
application/NN
of/IN
gene-expression/NN
profiling/VBG
to/TO
the/DT
differentiation/NN
of/IN
AML/NN
and/CC
ALL/NN
./.
====================
As/IN
far/RB
as/IN
we/PRP
are/VBP
aware/JJ
,/,
this/DT
is/VBZ
the/DT
first/JJ
report/NN
of/IN
gene/NN
expression/NN
profiling/VBG
by/IN
oligo-nucleotide/JJ
Microarray/NN
analysis/NN
in/IN
hematological/JJ
malignancies/NNS
in/IN
Korea/NN
./.
====================
Patients/NNS
diagnosed/VBN
with/IN
AML/NN
or/CC
ALL/NN
with/IN
available/JJ
peripheral/JJ
blood/NN
samples/NNS
available/JJ
for/IN
analyses/NNS
were/VBD
enrolled/VBN
in/IN
this/DT
study/NN
./.
====================
A/DT
total/JJ
of/IN
47/CD
patients/NNS
were/VBD
analyzedat/RB
the/DT
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
,/,
Inha/NN
University/NN
Hospital/JJ
,/,
Gachon/NNP
University/NN
Gil/NN
Medical/JJ
Center/NN
,/,
Hallym/NNP
University/NN
Medical/JJ
Center/NN
,/,
and/CC
at/IN
the/DT
Korean/JJ
Cancer/NN
Center/NN
Hospital/JJ
(/(
Table/JJ
1/CD
)/)
./.
====================
Mononuclear/JJ
cells/NNS
were/VBD
isolated/VBN
from/IN
peripheral/JJ
blood/NN
bycentrifugation/NN
on/IN
a/DT
Ficoll/NN
Hypaque/NN
(/(
density/NN
,/,
1.077/CD
;/:
APB/NN
,/,
Upsalla/FW
,/,
Sweden/JJ
)/)
density/NN
gradient/NN
./.
====================
Total/JJ
RNA/NN
from/IN
these/DT
cells/NNS
was/VBD
isolated/VBN
using/VBG
TRIZOL/NN
(/(
Gibco/NN
BRL/NN
,/,
NY/NN
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
Reference/NN
RNA/NN
was/VBD
obtained/VBN
from/IN
the/DT
Jerket/NN
cell/NN
line/NN
./.
====================
Total/JJ
RNA/NN
(/(
5/CD
pg/NN
)/)
was/VBD
converted/VBN
into/IN
double/JJ
stranded/JJ
cDNA/NN
using/VBG
the/DT
cDNA/NN
synthesis/NN
system/NN
(/(
Roche/NNP
)/)
using/VBG
T7-/JJ
(/(
dT/NN
)/)
24/CD
primer/NN
./.
====================
The/DT
synthesized/VBN
cDNA/NN
was/VBD
purified/VBN
using/VBG
RNeasy/NN
kits/NNS
(/(
Qiagen/NN
,/,
Valencia/NN
,/,
http/NN
:/:
//mvw.qiagen/NN
./.
====================
com/IN
)/)
,/,
and/CC
prepared/VBN
cDNAs/NNS
were/VBD
labeled/VBN
with/IN
Cy5-UTP/NN
(/(
for/IN
reference/NN
RNA/NN
)/)
or/CC
Cy3-UTP/NN
(/(
for/IN
test/NN
samples/NNS
)/)
using/VBG
Megascript/NN
T7/NN
kits/NNS
(/(
Ambionm/NNP
Austin/NN
)/)
./.
====================
cRNAs/NNS
were/VBD
cleaned/VBN
using/VBG
RNeasy/NN
(/(
Qiagen/NN
)/)
./.
====================
Labeled/JJ
15/CD
pg/NN
of/IN
each/DT
cRNA/NN
was/VBD
mixed/VBN
and/CC
fragmented/JJ
by/IN
heating/VBG
to/TO
94°C/NN
for/IN
15/CD
min/NN
,/,
and/CC
hybridized/VBD
with/IN
a/DT
Human/JJ
10/CD
K/NN
microarray/NN
(/(
Macrogen/NN
,/,
Seoul/JJ
,/,
Korea/NN
)/)
for/IN
16h/JJ
at/IN
42°C/NN
./.
====================
Arrays/NNS
were/VBD
then/RB
washed/VBD
and/CC
scanned/VBD
with/IN
an/DT
Array/NN
scanner/NN
(/(
Molecular/JJ
Dynamics/NNS
)/)
./.
====================
Acquired/VBN
images/VBZ
were/VBD
processed/VBN
and/CC
analyzed/VBD
statistically/RB
with/IN
respected/JJ
to/TO
spot/VB
intensities/NNS
using/VBG
an/DT
Imagene/NN
v4.1/NN
software/JJ
(/(
Biodiscovery/NNP
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
To/TO
normalize/VB
microarray/NN
data/NNS
,/,
we/PRP
used/VBD
the/DT
within/IN
pin/NN
group/NN
,/,
intensity/NN
dependent/JJ
Loess/NN
method/NN
./.
====================
An/DT
‘/NN
MA-plot/NN
’/CD
was/VBD
used/VBN
to/TO
represent/VB
the/DT
R/NN
and/CC
G/NN
data/NNS
,/,
where/WRB
====================
M=log/NN
2/CD
R/G/NN
and/CC
A=log/NN
2/CD
(/(
RG/NN
)/)
1/2/CD
;/:
R/NN
represents/VBZ
the/DT
F635/NN
====================
signal/NN
from/IN
Cy-5/NN
and/CC
G/NN
the/DT
F532/NN
signal/NN
from/IN
Cy-3/NN
labeling/NN
./.
====================
To/TO
correct/VB
for/IN
pin/NN
variation/NN
,/,
within/IN
pin/NN
group/NN
normalization/NN
’/CD
was/VBD
performed/VBN
./.
====================
Raw/NN
data/NNS
was/VBD
normalized/VBN
====================
relative/JJ
to/TO
a/DT
(/(
pin/NN
tip+A/NN
)/)
,/,
i.e/FW
./.
====================
log/NN
2/CD
R/G/NN
log/NN
2/CD
R/G-ci/NNP
(/(
A/DT
)/)
=/JJ
log/NN
2/CD
R//NN
[/(
ki/NNS
(/(
A/DT
)/)
G/NN
]/)
where/WRB
ci/NNS
(/(
A/DT
)/)
is/VBZ
the/DT
Lowess/JJ
fit/NN
to/TO
the/DT
MA-plot/NN
====================
for/IN
the/DT
i/LS
th/DT
pin/NN
group/NN
only/RB
,/,
i=1,2/NN
,/,
.../:
//:
and/CC
I/NN
denotes/VBZ
the/DT
number/NN
of/IN
pin/NN
groups/NNS
./.
====================
The/DT
normalized/VBN
data/NNS
was/VBD
filtered/VBN
using/VBG
the/DT
criteria/NNS
of/IN
missing/VBG
value/NN
>/JJR
20/CD
%/NN
in/IN
studied/VBN
samples/NNS
./.
====================
Remained/VBN
data/NNS
with/IN
missing/JJ
values/NNS
were/VBD
adjusted/VBN
using/VBG
the/DT
K/NN
nearest/JJS
neighborhood/NN
joining/VBG
method/NN
./.
====================
We/PRP
used/VBD
35/CD
samples/NNS
(/(
28/CD
AML/NN
and/CC
7/CD
ALL/NN
)/)
as/IN
a/DT
training/JJ
group/NN
and/CC
12/CD
samples/NNS
(/(
9/CD
AML/NN
and/CC
3/CD
ALL/NN
)/)
as/IN
a/DT
test/NN
group/NN
./.
====================
To/TO
identify/VB
differentially/RB
expressed/VBN
genes/NNS
,/,
which/WDT
discriminate/VBP
AML/NN
from/IN
ALL/NN
,/,
namely/RB
classifier/NN
genes/NNS
,/,
we/PRP
used/VBD
SAM/NN
(/(
Significant/JJ
Analysis/NN
of/IN
Micorarray/NN
)/)
./.
====================
Classifier/NN
genes/NNS
were/VBD
determined/VBN
using/VBG
FDR/NN
(/(
</JJR
0.05/CD
)/)
./.
====================
Selected/VBN
classifier/NN
genes/NNS
were/VBD
validated/VBN
by/IN
class/NN
prediction/NN
using/VBG
====================
Gaussian/JJ
linear/JJ
discriminant/JJ
analysis/NN
in/IN
the/DT
independent/JJ
test/NN
group/NN
./.
====================
CLUSTER/NN
and/CC
TREEVIEW/NN
were/VBD
used/VBN
for/IN
data/NNS
clustering/NN
and/CC
visualization/NN
(/(
Eisen/NNP
etal./FW
,/,
1998/CD
)/)
./.
====================
We/PRP
selected/VBD
35/CD
samples/NNS
as/IN
a/DT
training/JJ
group/NN
from/IN
the/DT
47/CD
samples/NNS
to/TO
reduce/VB
the/DT
effect/NN
of/IN
individual/JJ
variability/NN
./.
====================
After/IN
normalization/NN
and/CC
filtering/VBG
as/IN
described/VBN
above/IN
,/,
we/PRP
obtained/VBD
10,000/CD
gene/NN
expression/NN
data/NNS
,/,
which/WDT
were/VBD
available/JJ
for/IN
further/JJ
analysis/NN
./.
====================
Based/VBN
on/IN
the/DT
unsupervised/JJ
clustering/NN
of/IN
whole/JJ
samples/NNS
,/,
AML/NN
and/CC
ALL/NN
were/VBD
not/RB
====================
differentiable/JJ
due/JJ
to/TO
high/JJ
noise/RB
levels/NNS
in/IN
the/DT
expression/NN
data/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
To/TO
remove/VB
noise/RB
signals/NNS
and/CC
identify/VBP
genes/NNS
differentially/RB
expressed/VBN
in/IN
AML/NN
and/CC
ALL/NN
,/,
supervised/VBD
analysis/NN
was/VBD
performed/VBN
using/VBG
Significant/JJ
Analysis/NN
of/IN
Microarray/NN
(/(
SAM/NN
)/)
./.
====================
Genes/NNS
were/VBD
selected/VBN
using/VBG
a/DT
False/JJ
Discovery/NN
Rate/NN
(/(
FDR/NN
)/)
of/IN
</JJR
0.05/CD
as/IN
threshold/RB
,/,
and/CC
345/CD
genes/NNS
were/VBD
found/VBN
to/TO
be/VB
at/IN
significantly/RB
different/JJ
levels/NNS
in/IN
AML/NN
and/CC
ALL/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
We/PRP
selected/VBD
265/CD
over-expressed/VBN
genes/NNS
in/IN
ALL/NN
and/CC
80over-/NN
expressed/VBN
genes/NNS
in/IN
AML/NN
compared/VBN
to/TO
the/DT
other/JJ
classes/NNS
(/(
Hg/NN
./.
====================
2/CD
)/)
./.
====================
To/TO
verify/VB
the/DT
selected/VBN
classifier/NN
genes/NNS
,/,
we/PRP
performed/VBD
class/NN
predictions/NNS
with/IN
classifier/NN
genes/NNS
in/IN
the/DT
test/NN
group/NN
,/,
which/WDT
consisted/VBD
of/IN
9/CD
AML/NN
and/CC
3/CD
ALL/NN
patients/NNS
./.
====================
A/DT
cross-validation/NN
and/CC
a/DT
test/NN
error/NN
rate/NN
calculation/NN
were/VBD
performed/VBN
with/IN
PAM/NN
using/VBG
345/CD
genes/NNS
./.
====================
Our/PRP$
data/NNS
showed/VBD
a/DT
remarkable/JJ
ability/NN
to/TO
discriminate/VB
between/IN
AML/NN
and/CC
ALL/NN
in/IN
the/DT
test/NN
group/NN
./.
====================
Finally/RB
,/,
we/PRP
successfully/RB
discriminated/VBN
all/DT
AML/NN
and/CC
ALL/NN
patients/NNS
using/VBG
these/DT
345/CD
classifier/NN
genes/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Genes/NNS
that/WDT
showed/VBD
relatively/RB
high/JJ
expression/NN
in/IN
AML/NN
pa­/NN
tients/NNS
were/VBD
deoxynucleotidyl/JJ
transferase/NN
,/,
pre-B/JJ
lympho­/JJ
cyte/NN
gene/NN
3/CD
,/,
B-cell/NN
linker/NN
,/,
CD9/NN
antigen/NN
,/,
lymphoid/JJ
en­/JJ
hancer-binding/VBG
factor/NN
1/CD
,/,
CD79B/NN
antigen/NN
,/,
and/CC
early/JJ
B-cell/NN
factor/NN
(/(
Fig/NN
./.
====================
4a/CD
)/)
./.
====================
Genes/NNS
highly/RB
expressed/VBN
in/IN
ALL/NN
patients/NNS
were/VBD
annexin/NN
A1/NN
,/,
amyloid/JJ
beta/NN
(/(
A4/NN
)/)
precursor/NN
protein/NN
,/,
amyloid/JJ
beta/NN
(/(
A4/NN
)/)
precursor-like/JJ
protein/NN
2/CD
,/,
cathepsin/NN
C/NN
,/,
ly­/JJ
sozyme/RB
(/(
renal/JJ
amyloidosis/NN
)/)
,/,
myeloperoxidase/JJ
,/,
and/CC
hema­/RB
topoietic/JJ
prostaglandin/NN
D2/NN
synthase/NN
(/(
Fig/NN
./.
====================
4b/NN
)/)
./.
====================
Microarray/NN
technology/NN
has/VBZ
been/VBN
applied/VBN
to/TO
haematological/JJ
malignancy/NN
studies/NNS
on/IN
disease/NN
classification/NN
,/,
outcome/NN
prediction/NN
,/,
pathway/NN
delineation/NN
,/,
and/CC
target/NN
identification/NN
./.
====================
Some/DT
of/IN
this/DT
work/NN
has/VBZ
been/VBN
very/RB
successful/JJ
,/,
and/CC
these/DT
successes/NNS
encouraged/VBN
some/DT
to/TO
declare/VB
the/DT
dawn/JJ
of/IN
a/DT
new/JJ
era/NNS
of/IN
quantitative/JJ
and/CC
predictive/JJ
biology/NN
,/,
in/IN
which/WDT
networks/NNS
of/IN
gene/NN
interactions/NNS
will/MD
be/VB
unraveled/JJ
and/CC
mathematical/JJ
algorithms/NNS
will/MD
be/VB
used/VBN
to/TO
diagnose/VB
diseases/NNS
,/,
model/NN
disease/NN
progression/NN
,/,
and/CC
predict/VBP
outcome/NN
and/CC
response/NN
to/TO
====================
By/IN
the/DT
middle/JJ
of/IN
2003/CD
over/IN
a/DT
hundred/JJ
publications/NNS
concerned/VBD
direct/JJ
or/CC
indirect/JJ
applications/NNS
of/IN
DNA/NN
microarrays/NNS
to/TO
haematological/JJ
malignancies/NNS
(/(
Ebert/NN
eta/NN
!/CD
./.
,/,
2004/CD
;/:
Margalit/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
These/DT
studies/NNS
fell/NN
into/IN
several/JJ
overlapping/VBG
areas/NNS
./.
====================
The/DT
first/JJ
type/NN
involved/VBN
basic/JJ
profiling/VBG
studies/NNS
,/,
which/WDT
concerned/VBD
the/DT
origins/NNS
and/CC
aetiologies/NNS
of/IN
tumors/NNS
./.
====================
These/DT
studies/NNS
often/RB
involved/VBN
comparing/VBG
tumor/NN
gene/NN
signatures/NNS
with/IN
signatures/NNS
of/IN
cells/NNS
at/IN
a/DT
particular/JJ
haematological/JJ
stage/NN
of/IN
development/NN
./.
====================
Alternatively/RB
,/,
the/DT
nature/NN
of/IN
aberrant/JJ
gene/NN
expression/NN
compared/VBN
with/IN
the/DT
nearest/JJ
normal/JJ
cell/NN
type/NN
may/MD
be/VB
examined/VBN
to/TO
reveal/VB
details/VBZ
of/IN
the/DT
mechanism/NN
of/IN
tumorigenesis/NN
or/CC
tumor/NN
maintenance/NN
./.
====================
The/DT
second/JJ
type/NN
of/IN
study/NN
could/MD
be/VB
described/VBN
as/IN
classification/NN
studies/NNS
,/,
in/IN
which/WDT
the/DT
aim/NN
was/VBD
to/TO
identify/VB
the/DT
minimum/JJ
set/NN
of/IN
genes/NNS
required/VBN
to/TO
define/VB
a/DT
particular/JJ
tumor/NN
or/CC
tumor/NN
subclass/NN
./.
====================
Typically/RB
this/DT
study/NN
type/NN
follows/VBZ
on/IN
profiling/VBG
studies/NNS
and/CC
employs/VBZ
supervised/VBD
clustering/NN
coupled/VBN
with/IN
a/DT
machine/NN
learning/VBG
algorithm/NN
or/CC
another/DT
type/NN
of/IN
statistical/JJ
classifier/NN
./.
====================
The/DT
best/JJS
of/IN
these/DT
studies/NNS
have/VBP
attempted/VBN
to/TO
independently/RB
cross-validate/VBP
the/DT
classifier/NN
set/NN
using/VBG
further/JJ
arrays/NNS
or/CC
conventional/JJ
approaches/NNS
in/IN
a/DT
new/JJ
tumor/NN
sets/NNS
./.
====================
The/DT
third/JJ
type/NN
of/IN
study/NN
involves/VBZ
the/DT
identification/NN
of/IN
diagnostic/JJ
and/CC
prognostic/JJ
markers/NNS
./.
====================
In/IN
this/DT
case/NN
,/,
supervised/VBD
learning/VBG
approaches/NNS
are/VBP
employed/VBN
that/WDT
are/VBP
similar/JJ
to/TO
associate/VB
a/DT
particular/JJ
profile/NN
with/IN
a/DT
knownoutcome/JJ
,/,
the/DT
aim/NN
being/VBG
to/TO
identify/VB
a/DT
small/JJ
subclass/NN
of/IN
genes/NNS
with/IN
predictive/JJ
capability/NN
./.
====================
This/DT
might/MD
,/,
for/IN
example/NN
,/,
be/VB
coupled/VBN
to/TO
a/DT
Kaplan-Meier/NN
survival/NN
curve/JJ
to/TO
predict/VB
outcome/NN
for/IN
different/JJ
tumor/NN
subsets/NNS
,/,
or/CC
to/TO
predict/VB
relapse/NN
or/CC
response/NN
to/TO
treatment/NN
./.
====================
It/PRP
is/VBZ
important/JJ
to/TO
note/VB
that/IN
such/JJ
classifiers/NNS
can/MD
only/RB
be/VB
applied/VBN
to/TO
defined/VBN
tumor/NN
subsets/NNS
./.
====================
Genes/NNS
highly/RB
expressed/VBN
in/IN
ALL/NN
in/IN
the/DT
present/JJ
study/NN
have/VBP
been/VBN
associated/VBN
with/IN
the/DT
pathogenesis/NN
of/IN
lymphoid/JJ
leukemias/NNS
./.
====================
For/IN
example/NN
,/,
annexin/NN
A1/NN
was/VBD
highly/RB
expressed/VBN
in/IN
ALL/NN
patients/NNS
./.
====================
It/PRP
was/VBD
also/RB
reported/VBD
to/TO
be/VB
a/DT
simple/JJ
diagnostic/JJ
marker/NN
for/IN
hairy/JJ
cell/NN
leukemia/NN
with/IN
an/DT
accuracy/NN
of/IN
100/CD
%/NN
according/VBG
to/TO
a/DT
previous/JJ
report/NN
(/(
Falini/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Amyloid/JJ
precursor/NN
protein/NN
has/VBZ
been/VBN
hypothesized/VBN
to/TO
be/VB
related/JJ
with/IN
unknown/JJ
molecular/JJ
mechanisms/NNS
involved/VBN
in/IN
leukemogenesis/NN
with/IN
ERG/NN
and/CC
ETS2/NN
(/(
Baldus/NNP
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Moreover/RB
,/,
cathepsin/NN
C/NN
was/VBD
proposed/VBN
to/TO
be/VB
a/DT
significant/JJ
gene/NN
for/IN
large/JJ
granular/JJ
lymphocyte/NN
(/(
LGL/NN
)/)
leukemia/NN
identification/NN
by/IN
expression/NN
profiling/VBG
(/(
Kothapalli/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Genes/NNS
highly/RB
expressed/VBN
in/IN
AML/NN
include/VBP
B-cell/NN
related/JJ
genes/NNS
,/,
such/JJ
as/IN
pre-B/JJ
lymphocyte/NN
gene/NN
3/CD
,/,
B-cell/NN
linker/NN
,/,
lymphoid/JJ
enhancer-binding/JJ
factor/NN
1/CD
,/,
and/CC
early/JJ
B-cell/NN
factor/NN
./.
====================
The/DT
mechanism/NN
linking/VBG
these/DT
genes/NNS
to/TO
AML/NN
is/VBZ
not/RB
clear/JJ
,/,
which/WDT
needs/VBZ
further/RBR
investigations/NNS
./.
====================
The/DT
classifiers/NNS
of/IN
this/DT
study/NN
do/VBP
not/RB
show/VB
high/JJ
concordance/NN
compared/VBN
to/TO
previous/JJ
studies/NNS
./.
====================
Golub/NN
et/FW
al/JJ
./.
====================
used/VBN
50/CD
predictor/NN
genes/NNS
to/TO
discriminate/VB
AML/NN
from/IN
ALL/NN
(/(
Golub/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
Twenty-five/CD
genes/NNS
were/VBD
chosen/NN
that/DT
were/VBD
more/RBR
highly/RB
expressed/VBN
in/IN
AML/NN
and/CC
25/CD
genes/NNS
were/VBD
more/RBR
highly/RB
expressed/VBN
in/IN
ALL/NN
./.
====================
None/NN
of/IN
the/DT
genes/NNS
,/,
however/RB
,/,
were/VBD
chosen/NN
in/IN
the/DT
present/JJ
study/NN
in/IN
Korean/JJ
population/NN
./.
====================
Although/IN
in/IN
the/DT
past/NN
years/NNS
gene/NN
expression/NN
profiling/VBG
has/VBZ
indeed/RB
shown/VBN
great/JJ
promise/VBP
with/IN
regard/NN
to/TO
the/DT
classification/NN
of/IN
leukemia/NN
,/,
one/CD
should/MD
also/RB
take/VBP
its/PRP$
limitations/NNS
into/IN
account/VBP
./.
====================
The/DT
limitations/NNS
of/IN
gene/NN
expression/NN
profiling/VBG
are/VBP
evident/JJ
if/IN
the/DT
results/NNS
of/IN
different/JJ
gene/NN
expression/NN
profiling/VBG
studies/NNS
are/VBP
compared/VBN
./.
====================
The/DT
quality/NN
of/IN
materials/NNS
used/VBN
,/,
sample/JJ
processing/NN
,/,
the/DT
application/NN
of/IN
different/JJ
expression/NN
platforms/VBZ
and/CC
the/DT
wide/JJ
variety/NN
of/IN
methods/NNS
used/VBN
for/IN
pattern/NN
discovery/RB
,/,
make/VBP
the/DT
proper/JJ
validation/NN
of/IN
the/DT
results/NNS
of/IN
different/JJ
studies/NNS
difficult/JJ
./.
====================
In/IN
Korea/NN
,/,
several/JJ
reports/NNS
have/VBP
been/VBN
issued/VBN
on/IN
microarray/NN
technology/NN
./.
====================
However/RB
,/,
to/TO
date/NN
no/DT
report/NN
has/VBZ
been/VBN
issued/VBN
on/IN
the/DT
use/NN
of/IN
this/DT
technology/NN
in/IN
acute/JJ
leukemia/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
identified/VBD
gene/NN
expression/NN
profiles/NNS
that/WDT
differentiae/VBP
AML/NN
and/CC
ALL/NN
./.
====================
We/PRP
hope/VBP
that/DT
this/DT
approach/NN
may/MD
provide/VB
broad/JJ
access/VBP
to/TO
high-quality/JJ
diagnoses/NNS
and/CC
treatment/NN
guidance/NN
in/IN
leukemia/NN
./.
====================
